SEC Comment Letter for Protalix BioTherapeutics, Inc. (PLX) (CIK 0001006281) (PLX) — Mar 15, 2019

Protalix BioTherapeutics, Inc. (PLX) (CIK 0001006281)
Date: March 15, 2019 · CIK: 0001006281 · Accession: 0000000000-19-004851

View on Edgar

AI Filing Summary & Sentiment

Sentiment

Urgency

Document Type

Confidence

SEC Posture

Company Posture

Summary

Reasoning

File numbers found in text: 001-33357

Date

March 14, 2019

Author

Yossi Maimon

Form

UPLOAD

Company

Protalix BioTherapeutics, Inc. (PLX) (CIK 0001006281)

Letter

March 14, 2019 Yossi Maimon Chief Financial Officer Protalix BioTherapeutics, Inc. 2 Snunit Street Science Park POB 455 Carmiel, Israel 20100 Re:Protalix BioTherapeutics, Inc. Form 10-K for the Fiscal Year Ended December 31, 2017 Filed March 6, 2018 File No. 001-33357 Dear Mr. Maimon: We have completed our review of your filings. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Sincerely, Division of Corporation Finance Office of Healthcare & Insurance

Show Raw Text

March 14, 2019
Yossi Maimon
Chief Financial Officer
Protalix BioTherapeutics, Inc.
2 Snunit Street
Science Park
POB 455
Carmiel, Israel 20100
Re:Protalix BioTherapeutics, Inc.
Form 10-K for the Fiscal Year Ended December 31, 2017
Filed March 6, 2018
File No. 001-33357
Dear Mr. Maimon:
            We have completed our review of your filings.  We remind you that the company and its
management are responsible for the accuracy and adequacy of their disclosures, notwithstanding
any review, comments, action or absence of action by the staff.
Sincerely,
Division of Corporation Finance
Office of Healthcare & Insurance

SecProbe.io